Post GLP 1 Weight Maintenance And Gene Therapy Will Reshape Long Term Metabolic Care

Catalysts

About Fractyl Health

Fractyl Health focuses on endoscopic and genetic therapies that target root causes of obesity and type 2 diabetes.

What are the underlying business or industry changes driving this perspective?

• Growing use of GLP-1 drugs for obesity and type 2 diabetes is creating a large and recurring pool of patients who eventually discontinue therapy and then struggle with weight regain. Revita is positioned as a dedicated post GLP-1 weight maintenance procedure that could directly support procedure volumes and future revenue.
• Clinical data such as the REMAIN-1 Midpoint Cohort and German registry outcomes suggest Revita may offer durable weight loss and glycemic benefits with a single procedure. If reflected in broader real-world use, this could support reimbursement decisions and longer term earnings power.
• The company’s clinical execution, including REMAIN-1 pivotal enrollment progressing ahead of schedule and multiple planned data readouts through 2026, creates a steady flow of potential value inflection points that could influence how investors view future revenue and margin prospects.
• Embedding Revita into existing high volume endoscopy workflows, along with unit economics that management expects to be comparable to or better than other advanced endoscopic interventions, may help drive adoption at clinical sites and support gross margin and operating leverage over time.
• The Rejuva Smart GLP-1 gene therapy platform, with RJVA-001 and RJVA-002 targeting long lasting, physiologic GLP-1 based effects, expands Fractyl’s reach beyond procedures into potential long duration metabolic treatments. This could diversify future revenue streams and support earnings when combined with Revita.

Assumptions

This narrative explores a more optimistic perspective on Fractyl Health compared to the consensus, based on a Fair Value that aligns with the bullish cohort of analysts. How have these above catalysts been quantified?

• The bullish analysts are assuming Fractyl Health's revenue will grow by 4457.6% annually over the next 3 years.
• The bullish analysts are not forecasting that Fractyl Health will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Fractyl Health's profit margin will increase from -4073233.3% to the average US Medical Equipment industry of 12.9% in 3 years.
• If Fractyl Health's profit margin were to converge on the industry average, you could expect earnings to reach $36.7 million (and earnings per share of $0.22) by about January 2029, up from $-122.2 million today.
• In order for the above numbers to justify the price target of the more bullish analyst cohort, the company would need to trade at a PE ratio of 58.0x on those 2029 earnings, up from -2.3x today. This future PE is greater than the current PE for the US Medical Equipment industry at 29.9x.
• The bullish analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 8.17%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• Revita and the Rejuva gene therapy programs are still in clinical development, and the business case relies heavily on future pivotal data, regulatory approvals and reimbursement decisions. Any unfavorable outcomes on efficacy, safety, or durability could limit procedure volumes and product uptake, putting long term revenue and earnings under pressure.
• The company is investing heavily in research and development, with R&D expenses of US$17.5 million in the third quarter of 2025 and a reported net loss of US$45.6 million for the quarter. If this level of spending needs to continue beyond the current cash runway into early 2027 without offsetting revenue, it could require further dilutionary equity raises that weigh on per share earnings.
• The narrative assumes a large future opportunity in post GLP 1 weight maintenance. However, long term outcomes will depend on how payers, physicians and patients accept an endoscopic procedure without existing CPT codes. If reimbursement and adoption are slower or narrower than expected, that could cap procedure volumes, limiting revenue growth and constraining margin improvement.
• Competition from current and next generation GLP 1 based drugs and other metabolic treatments may change how obesity and type 2 diabetes are treated over time. If drug regimens evolve in a way that reduces the perceived need for a procedural off ramp such as Revita, the potential addressable market could be smaller than anticipated, affecting long term revenue, gross margin and earnings.
• The Rejuva Smart GLP 1 platform, including RJVA 001 and RJVA 002, is at an early stage, with first patient dosing and only preliminary data targeted for 2026. Technical, safety or regulatory setbacks in gene therapy could delay or limit commercialization, leaving the company more dependent on a single procedure based revenue stream and increasing the risk to future margins and earnings.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bullish price target for Fractyl Health is $10.0, which represents up to two standard deviations above the consensus price target of $7.44. This valuation is based on what can be assumed as the expectations of Fractyl Health's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.
  
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $10.0, and the most bearish reporting a price target of just $5.0.
  
• In order for you to agree with the more bullish analyst cohort, you'd need to believe that by 2029, revenues will be $284.0 million, earnings will come to $36.7 million, and it would be trading on a PE ratio of 58.0x, assuming you use a discount rate of 8.2%.
  
• Given the current share price of $2.06, the analyst price target of $10.0 is 79.4% higher.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.